Drug Trial Radar · NCT06555783
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Jul 26, 2024
Primary completion
Nov 11, 2025
Study completion Nov 21, 2025
Sponsor
- Lead sponsor
- Alkermes, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Conditions
- Narcolepsy Type 2
Interventions
ALKS 2680Drug
Oral tablet containing ALKS 2680
PlaceboDrug
Oral tablet containing placebo for once daily administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Mean Sleep Latency (MSL) on the Maintenance Wakefulness Test (MWT)Time frame: Baseline to Week 8
- Change in Epworth Sleepiness Scale (ESS)Time frame: Baseline to week 8
Locations
47 sites in 8 countries. Site status is shown where the registry gives one.
Alkermes Investigator Site
Little Rock, Arkansas
Alkermes Investigator Site
Los Angeles, California
Alkermes Investigator Site
Redwood City, California
Alkermes Investigator Site
San Francisco, California
Alkermes Investigator Site
Santa Ana, California
Alkermes Investigational Site
Aurora, Colorado
Alkermes Investigator Site
Colorado Springs, Colorado
Alkermes Investigator Site
Brandon, Florida
Alkermes Investigator Site
Miami, Florida
Alkermes Investigator Site
Winter Park, Florida
Alkermes Investigator Site
Atlanta, Georgia
Alkermes Investigational Site
Macon, Georgia
Alkermes Investigator Site
Stockbridge, Georgia
Alkermes Investigational Site
Peoria, Illinois
Alkermes Investigator Site
Lansing, Michigan
Alkermes Investigator Site
Sterling Heights, Michigan
Alkermes Investigator Site
Lincoln, Nebraska
Alkermes Investigator Site
Middletown, New Jersey
Alkermes Investigator Site
Denver, North Carolina
Alkermes Investigator Site
Huntersville, North Carolina
Alkermes Investigator Site
Canton, Ohio
Alkermes Investigator Site
Cincinnati, Ohio
Alkermes Investigator Site
Cincinnati, Ohio
Alkermes Investigational Site
Cleveland, Ohio
Alkermes Investigator Site
Abington, Pennsylvania
Alkermes Investigational Site
Philadelphia, Pennsylvania
Alkermes Investigator Site
Wyomissing, Pennsylvania
Alkermes Investigator Site
Columbia, South Carolina
Alkermes Investigator Site
Cordova, Tennessee
Alkermes Investigator Site
Austin, Texas
Alkermes Investigator Site
San Antonio, Texas
Alkermes Investigational Site
Sugar Land, Texas
Alkermes Investigational Site
Madison, Wisconsin
Alkermes Investigator Site
Macquarie Park, New South Wales, Australia
Alkermes Investigator Site
Bedford Park, South Australia, Australia
Alkermes Investigational Site
Alken, Belgium
Alkermes Investigational Site
Namur, Belgium
Alkermes Investigational Site
Prague, Czechia
Alkermes Investigational Site
Bordeaux, France
Alkermes Investigational Site
La Tronche, France
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.